-
Merck & Co. Inc. (NYSE:MRK) said it no longer plans to submit regulatory applications for preladenant to treat Parkinson's disease after an initial review of data from three double-blind Phase III trials "did not …
Published on 5/23/2013
-
Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said once-daily 3 mg subcutaneous liraglutide met the three co-primary endpoints in the Phase IIIa SCALE Obesity and Pre-diabetes trial to treat obesity. Liraglutide reduced mean …
Published on 5/23/2013
-
Salix Pharmaceuticals Inc. (NASDAQ:SLXP) said budesonide rectal foam given twice daily for two weeks and then once daily for four weeks met the primary endpoint in a pair of Phase III trials to treat ulcerative colitis…
Published on 5/22/2013
-
Upsher-Smith Laboratories Inc. (Maple Grove, Minn.) said on Wednesday that once-daily USL255 as adjunctive therapy met the primary endpoint in the Phase III PREVAIL trial, and that FDA accepted for review an NDA for …
Published on 5/22/2013
-
Novartis AG (NYSE:NVS; SIX:NOVN) said once-daily QVA149 met the primary endpoint of improving patient self-reported shortness of breath during daily activities as measured by Transition Dyspnea Index (TDI) scores from …
Published on 5/21/2013
-
Aduro BioTech Inc. (Berkeley, Calif.) stopped early a Phase II trial evaluating CRS-207 plus GVAX Pancreas cancer vaccine and cyclophosphamide to treat pancreatic cancer after the combination met the primary endpoint of…
Published on 5/20/2013
-
H. Lundbeck A/S (CSE:LUN) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) presented additional data on Monday showing that some doses of Brintellix vortioxetine significantly improved depression rating scores …
Published on 5/20/2013
-
Pfizer Inc. (NYSE:PFE) said it discontinued the Phase III B1931008 trial evaluating inotuzumab ozogamicin to treat relapsed or refractory CD22-positive aggressive non-Hodgkin's lymphoma. The move came after an interim …
Published on 5/20/2013
-
XenoPort Inc. (NASDAQ:XNPT) fell $1.03 (15%) to $5.72 on Monday after discontinuing development of arbaclofen placarbil based on top-line data showing that twice-daily doses of the product missed the co-primary …
Published on 5/20/2013
-
Novo Nordisk A/S (CSE:NVO; NYSE:NVO) reported data on Friday from the 74-patient Phase III paradigm 2 trial evaluating N9-GP -- a glyco-pegylated derivative of recombinant human Factor IX -- to treat and prevent …
Published on 5/17/2013
-
ThromboGenics N.V. (Euronext:THR) disclosed in a business update for the period ending April 30 that ocriplasmin missed the primary endpoint in the Phase IIa MIVI-5 trial to treat focal vitreomacular adhesion (VMA) …
Published on 5/17/2013
-
Halozyme Therapeutics Inc. (NASDAQ:HALO) gained $1.24 (18%) to $7.98 on Thursday after reporting data from 24 evaluable patients in the open-label, dose-escalation Phase Ib portion of a Phase I/II trial to treat …
Published on 5/16/2013
-
Helsinn Healthcare S.A. (Pazzallo-Lugano, Switzerland) said a single dose of its oral Netu-palo-FDC (NEPA) plus dexamethasone was superior to a single dose of oral palonosetron plus dexamethasone on the primary endpoint…
Published on 5/16/2013
-
Oncothyreon Inc. (NASDAQ:ONTY) fell $0.64 (25%) to $1.97 on Thursday after reporting data from two Phase II trials of once-daily oral PX-866 to treat recurrent glioblastoma multiforme (GBM) and recurrent or metastatic …
Published on 5/16/2013
-
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said once-daily 25 and 50 mg oral fasiglifam each met the primary endpoint of reducing HbA1c from baseline to week 24 vs. placebo in the Phase III CCT-003 trial to treat Type …
Published on 5/16/2013
-
Bristol-Myers Squibb Co. (NYSE:BMY) reported interim data late Wednesday from 52 evaluable patients showing that concurrent dosing with the pharma's Yervoy ipilimumab plus nivolumab led to an objective response rate (…
Published on 5/15/2013
-
The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said IV MPDL3280A once every three weeks led to an objective response rate (ORR) of 21% in 140 patients with locally advanced or metastatic solid tumors whose …
Published on 5/15/2013
-
Bharat Biotech International Ltd. (Hyderabad, India) said oral Rotavac significantly reduced severe rotavirus diarrhea by 56% during the first year of life vs. placebo in an Indian Phase III trial to prevent rotavirus …
Published on 5/14/2013
-
Eli Lilly and Co. (NYSE:LLY) discontinued development of enzastaurin (LY31765) after top-line data showed daily enzastaurin missed the primary endpoint of improving disease-free survival (DFS) vs. placebo in the Phase …
Published on 5/10/2013
-
Oncothyreon Inc. (NASDAQ:ONTY) disclosed in its 1Q13 earnings late Thursday that once-daily oral PX-866 plus docetaxel missed the primary endpoint of improving progression-free survival (PFS) vs. docetaxel alone in a …
Published on 5/10/2013
-
Italian researchers reported that a once-daily 1 g dose of N-3 polyunsaturated fatty acids missed the primary endpoint in a Phase III trial in 12,513 patients with multiple cardiovascular risk factors or atherosclerotic…
Published on 5/8/2013
-
Baxter International Inc. (NYSE:BAX) said both 200 and 400 mg/kg doses of IV Gammagard Liquid 10% given every two weeks missed the co-primary endpoints in the 390-patient Phase III GAP trial (Study 160701) to treat mild…
Published on 5/7/2013
-
Celgene Corp. (NASDAQ:CELG) reported additional data for apremilast on Monday and also announced revenue guidance for the oral phosphodiesterase-4 (PDE-4) inhibitor. In the Phase III PALACE-4 trial to treat psoriatic …
Published on 5/6/2013
-
Gilead Sciences Inc. (NASDAQ:GILD) reported interim data from the Phase II LONESTAR trial evaluating a once-daily, oral fixed-dose combination of sofosbuvir plus ledipasvir (GS-5885) to treat chronic HCV genotype 1 …
Published on 5/2/2013
-
Almirall S.A. (Madrid:ALM) and partner Forest Laboratories Inc. (NYSE:FRX) said twice-daily 400/12 ug aclidinium bromide/formoterol delivered via Almirall's Genuair inhaler met the co-primary endpoints in the Phase III …
Published on 5/1/2013